\
&
Contact us
\
&
Contact us
Published on | 1 day ago
Programmes HealthThe Global Health EDCTP3 Joint Undertaking has recently published its 2025 work programme . The calls for proposals will open in late January with a deadline for short proposals in March 2025 (first stage) and a deadline for full proposals (for succesful consortia) in September 2025.
The work programme includes four calls for proposals covering seven topics, with a total budget of €214 million. A pilot on lump sum contributions in the grant agreements for two call topics is being considered, and more flexible ways of working with contributing partners will be introduced to facilitate increased engagement with Global Health EDCTP3 and forge new and stronger partnerships.
Info days on the new work programme are expected to be organised in the coming weeks. The detailed information will be published on the NCP Flanders website as soon as it is available.
The Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) is a partnership between the European Union and the European and Developing Countries Clinical Trials Partnership (EDCTP) Association whose members are several EU Member States and Associated countries and several African countries.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
